Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.

International journal of chronic obstructive pulmonary disease·2025
Same author

A bronchial gene signature specific for severe COPD that is retained in the nose.

ERJ open research·2023
Same author

Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients.

Journal of clinical medicine·2023
Same author

Filling the Gap: A Feasibility Study of a COPD-Specific Breathlessness Service.

COPD·2022
Same author

Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2022
Same author

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.

Respiratory medicine·2021
Same journal

Rheumatoid arthritis: previously untreated early disease.

BMJ clinical evidence·2016
Same journal

Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.

BMJ clinical evidence·2016
Same journal

Subarachnoid haemorrhage (spontaneous aneurysmal).

BMJ clinical evidence·2016
Same journal

Malaria: fluid therapy in severe disease.

BMJ clinical evidence·2016
Same journal

Age-related macular degeneration: anti-vascular endothelial growth factor treatment.

BMJ clinical evidence·2016
Same journal

MRSA: treating people with infection.

BMJ clinical evidence·2016
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Bronchiectasis.

Nick ten Hacken1, Huib Kerstjens, Dirkje Postma

  • 1Pulmonary Department, University Hospital Groningen, Groningen, The Netherlands.

BMJ Clinical Evidence
|May 20, 2009
PubMed
Summary
This summary is machine-generated.

This systematic review evaluates treatments for bronchiectasis without cystic fibrosis, analyzing 16 studies on interventions like antibiotics, airway clearance, and inhaled therapies to assess effectiveness and safety.

Related Experiment Videos

Last Updated: Jun 23, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Area of Science:

  • Pulmonary Medicine
  • Respiratory Health
  • Clinical Evidence Synthesis

Background:

  • Bronchiectasis is a chronic lung condition often resulting from infections, characterized by persistent cough and sputum production.
  • It can mimic or coexist with chronic obstructive pulmonary disease and is linked to various congenital and acquired lung conditions.
  • This review specifically excludes cases associated with cystic fibrosis.

Purpose of the Study:

  • To systematically review the effects of various treatments for bronchiectasis in patients without cystic fibrosis.
  • To synthesize evidence on the efficacy and safety of different therapeutic interventions.

Main Methods:

  • A systematic literature search was conducted across major databases (Medline, Embase, Cochrane Library) up to July 2007.
  • Included studies comprised systematic reviews, randomized controlled trials (RCTs), and observational studies.
  • Evidence quality was assessed using the GRADE framework, and safety alerts from regulatory agencies were considered.

Main Results:

  • Sixteen relevant studies, including systematic reviews, RCTs, and observational studies, met the inclusion criteria.
  • The review analyzed a broad range of interventions for bronchiectasis management.

Conclusions:

  • The review provides information on the effectiveness and safety of multiple treatments for non-cystic fibrosis bronchiectasis.
  • Interventions covered include anticholinergic therapy, physical therapy, exercise, inhaled agents, leukotriene antagonists, methyl-xanthines, mucolytics, antibiotics, beta(2) agonists, steroids, and surgery.